Welcome to our dedicated page for Ocular Therapeut news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeut stock.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) generates frequent news as an ophthalmology-focused biopharmaceutical company advancing late-stage retinal programs and a commercial eye-care product. Its press releases highlight progress across the AXPAXLI (OTX-TKI) clinical programs in wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR), as well as updates related to DEXTENZA, financings, and corporate events.
News coverage for OCUL commonly includes clinical milestones such as target randomization in the SOL-R Phase 3 wet AMD trial, completion of randomization in SOL-1, and the initiation or advancement of the HELIOS Phase 3 registrational program in NPDR. The company also issues announcements about regulatory strategy, including Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration for SOL-1 and HELIOS-2 and plans to leverage the 505(b)(2) pathway for AXPAXLI in wet AMD.
Investors following OCUL news will see regular business and capital markets updates, such as underwritten equity offerings, cash runway disclosures, and inducement equity grants under Nasdaq Listing Rule 5635(c)(4). The company also reports quarterly financial results and business highlights, describing clinical execution, trial timelines, and planned extension studies like SOL-X for long-term evaluation of AXPAXLI in wet AMD.
In addition, Ocular Therapeutix announces participation in scientific and investor conferences, where it presents data from earlier-stage trials (for example, HELIOS Phase 1 results in NPDR) and discusses its strategy to "redefine the retina experience." For a consolidated view of these developments, the OCUL news page on Stock Titan brings together clinical, regulatory, financial, and corporate communications so readers can track how trial outcomes, regulatory interactions, and financing activities may shape the company’s ophthalmic pipeline and commercial portfolio over time.
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards under its 2019 Inducement Stock Incentive Plan to six newly hired non-executive employees (effective April 8, 2026) and to Jerome M. Gangitano, SVP, CMC Technical Operations (effective April 13, 2026).
The non-executive awards total options for 46,425 shares and RSUs for 15,275 shares with an $8.42 exercise price. Mr. Gangitano received options for 300,000 shares and RSUs for 100,000 shares with an $8.86 exercise price. Options have ten-year terms; vesting schedules are four years for options and three years for RSUs.
Ocular Therapeutix (NASDAQ: OCUL) reported additional Week 52 SOL-1 Phase 3 post-hoc analyses for AXPAXLI in wet AMD showing unmatched durability and sustained anatomic and visual control versus aflibercept.
Key data: median time to ≥30 uM CSFT increase was 39 weeks vs 16 weeks; median time to ≥75 uM was 46 weeks vs 24 weeks. Company plans NDA submission based on SOL-1 alone, subject to formal FDA discussions.
Ocular Therapeutix (NASDAQ: OCUL) will present additional data and analyses from the SOL-1 Phase 3 superiority trial of AXPAXLI (OTX-TKI) at multiple scientific conferences in April 2026.
Presentations occur at the Vit-Buckle Society meeting in Las Vegas on April 11 and at CNO 2026 in Buenos Aires on April 15, with a VBS slide copy to be posted on Ocular’s website after April 11.
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to three newly hired non-executive employees under its 2019 Inducement Stock Incentive Plan, effective March 6, 2026.
The awards comprise non-statutory stock options for an aggregate of 60,175 shares and restricted stock units for 19,975 shares. Options carry a $10.27 exercise price, a ten-year term, and a four-year vesting schedule; RSUs vest over three years with the first installment on March 6, 2027.
Ocular Therapeutix (NASDAQ: OCUL) will participate in multiple investor conferences in March 2026, including TD Cowen (March 2), Jefferies Biotech on the Beach (March 10), Citizens Life Sciences and Barclays (March 11) and RBC Ophthalmology (March 24).
Pravin U. Dugel, MD, Executive Chairman, President and CEO, will deliver several fireside chats. Live webcasts of TD Cowen, Citizens and RBC presentations will be available on the Investor Relations Events and Presentations page, with replays archived for at least 30 days.
Ocular Therapeutix (NASDAQ: OCUL) will present detailed SOL-1 Phase 3 superiority trial data for AXPAXLI (OTX-TKI) in wet AMD at the 49th Macula Society Annual Meeting on Feb 27, 2026, with presentations starting at 1:00 PM PT (4:00 PM ET).
The company will furnish symposium slides on Form 8-K at 4:00 PM ET on Feb 27 and host an investor webcast to discuss the data on Mar 2, 2026 at 7:30 AM ET; slides and a replay will be available on the company website.
Ocular Therapeutix (NASDAQ: OCUL) reported positive topline SOL-1 Phase 3 results for AXPAXLI in wet AMD on February 17, 2026. The trial met its FDA-aligned superiority primary endpoint at Week 36 (74.1% vs 55.8%, risk difference 17.5%, p=0.0006) and a durable Week 52 outcome (65.9% vs 44.2%, risk difference 21.1%, p<0.0001).
AXPAXLI showed higher rescue-free rates, superior Week 36 CSFT control (55.9% vs 37.8%, nominal p=0.0013), no treatment-related ocular SAEs, and plans to pursue an NDA pending FDA discussions. SOL-R non-inferiority trial continues with topline expected 1Q 2027.
Ocular Therapeutix (NASDAQ: OCUL) will host a webcast on Tuesday, February 17, 2026 at 8:00 AM ET to review topline results from the SOL-1 Phase 3 superiority trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration.
Detailed SOL-1 data will be presented at the 49th Macula Society Annual Meeting from February 25–28, 2026. The live webcast and archived replay (available for at least 30 days) can be accessed via the company's Investor Relations Events and Presentations page.
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to five newly hired non-executive employees effective February 2, 2026. The grants include non‑statutory stock options for an aggregate of 13,850 shares (exercise price $9.15) and restricted stock units for 4,600 shares.
Options have a ten‑year term and four‑year vesting (25% after one year, then monthly). RSUs vest over three years in equal annual installments, subject to continued service and award agreement terms under the 2019 Inducement Stock Incentive Plan.
Ocular Therapeutix (NASDAQ: OCUL) reported Q4 and full‑year 2025 results and business highlights on Feb 5, 2026. Key items: SOL‑1 Week 52 topline data expected at the 49th Macula Society meeting Feb 25–28, 2026; plan to file an NDA for AXPAXLI pending positive SOL‑1 results; SOL‑R randomized 631 subjects; cash of $737.1M supporting runway into 2028.
2025 revenue declined to $52.0M and net loss was $265.9M; R&D spending rose sharply to $197.1M.